ASH 2021 Conference Coverage on VuMedi

 

ASH 2021 Conference Coverage on VuMedi
Avatar

ASH 2021 Update on the “AAA” Risk Model for Essential Thrombocythemia: Age, ANC, and ALC

By ASH 2021 Conference Coverage on VuMedi FEATURING Ayalew Tefferi
By ASH 2021 Conference Coverage on VuMedi FEATURING Ayalew Tefferi
430 views
December 16, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
MDS and MPN
06:20
ASH 2021 Conference Coverage on VuMedi

Retrospective Head-to-Head Comparison Between Pacritinib and Ruxolit…

Feat. J. Mascarenhas
07:13
ASH 2021 Conference Coverage on VuMedi

FDA Approval and Safety Analysis of Pacritinib in Patients With Myel…

Feat. J. Mascarenhas
10:26
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on a Pooled Analysis of the COMFORT-I & II Stud…

Feat. S. Verstovsek
06:04
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Clinical and Pathological Characteristics of Hypocellular M…

Feat. K. Kim
05:14
ASH 2021 Conference Coverage on VuMedi

ASH 2021 NGS Evaluation of the EQoL-MDS Trial: Preliminary Analysis …

Feat. E. Oliva
11:04
ASH 2021 Conference Coverage on VuMedi

ASH 2021: Evaluation of IWG 2006 Response Criteria in Patients with …

Feat. J. Bewersdorf
06:52
ASH 2021 Conference Coverage on VuMedi

ASH 2021: A Phase 3 Study of Hepcidin Mimetic Rusfertide in Patients…

Feat. S. Verstovsek
11:17
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on the Management of Polycythemia Vera

Feat. A. Kuykendall
04:45
ASH 2021 Conference Coverage on VuMedi

ASH 2021 on LR-MDS: Factors Predicting Progression to HR-MDS and AML…

Feat. A. Jain
08:59
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on the Outcomes of Therapy-Related Myeloid Neoplasms…

Feat. M. Shah
08:12
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Efficacy and Safety of Parsaclisib+Ruxolitinib Combination …

Feat. A. Yacoub
08:30
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Presentation on Tagraxofusp, a First-in-Class CD123-Targete…

Feat. A. Yacoub
05:32
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Highlights on Ruxolitinib + Parsaclisib for JAK-/PI3K-Inhib…

Feat. A. Yacoub
08:15
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Highlights in MPN

Feat. P. Bose
15:25
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Clinical and Translational Data From the Ongoing MANIFEST T…

Feat. M. Kremyanskaya
10:43
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Final Results of a Phase 2 Study of Sotatercept for Anemia …

Feat. P. Bose
05:06
ASH 2021 Conference Coverage on VuMedi

Positioning Fedratinib in the Treatment Strategy of Myelofibrosis

Feat. F. Passamonti
13:17
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Molecular Responses in Treatment-Naïve HR-MDS Patients Trea…

Feat. J. Garcia
12:03
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Highlights on Efficacy and Safety of Sabatolimab for Patien…

Feat. A. Brunner
06:27
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on the Phase 2 Study of Bomedemstat (IMG-7289) In P…

Feat. H. Gill
07:56
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Rationale for and Results of a Phase I Study of the TGF-β 1…

Feat. J. Mascarenhas
10:27
Richard T. Silver

Splenomegaly in Polycythemia Vera: Clinical Significance and Relatio…

10:44
Aaron Gerds

A Real-World Evaluation of the Association Between Elevated Blood Co…

15:40
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on the “AAA” Risk Model for Essential Thrombocythemi…

Feat. A. Tefferi
05:15
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on Clinical Outcomes at 3 and 6 Months of Fedratinib…

Feat. J. Mascarenhas